Keybanc analyst Todd Thomas upgrades VICI Props (NYSE:VICI) from Sector Weight to Overweight.
BetterLife’s Non-Hallucinogenic LSD’s Clinical Studies, Braxia’s Psychedelic Treatments Continue
Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting Major Depressive Disorder (MDD.)
